Pulse Field Ablation for Atrial Fibrillation: A New Approach to Treating AFib
If you have atrial fibrillation and we've talked about rhythm control options, there's a good chance you've heard about catheter ablation. For years, the standard tools for ablation have been radiofrequency energy and cryogenic freezing. Both work well in the right hands, and I refer many patients for these procedures with excellent results. But in the last few years, a genuinely different technology has arrived: Pulse Field Ablation (PFA). It uses electrical pulses instead of heat or cold to create permanent scar in the atrium, and the early data suggest it may offer a safer and more effective option for some patients.
This article walks through what PFA is, how it differs from the older thermal ablation methods, which patients are good candidates, what the data actually show, and what the referral experience is like when I send someone for this procedure. My goal is to give you the real picture so you and I can make an informed decision about whether PFA is right for you.
What Pulse Field Ablation Actually Does
The goal of any ablation procedure is the same: to create permanent scar tissue in the atrium that blocks the chaotic electrical signals causing atrial fibrillation. The scarring disrupts the abnormal circuits that trigger and perpetuate AFib, and when done correctly, it can restore normal sinus rhythm or at least give us better rate control.
In a radiofrequency ablation, the electrophysiologist uses a catheter with a heated tip to burn the tissue. In a cryoablation, they freeze it. Both approaches have been proven to work. But they share some downsides. Heat and cold both damage tissue indiscriminately, which means they can injure nearby structures that you really don't want to damage, like the esophagus that sits right behind the atrium.
PFA works on a completely different principle. Instead of applying heat or cold, it delivers very brief, high-voltage electrical pulses directly to the tissue. These pulses create tiny holes in the cell membranes of the cardiac myocytes, a process called irreversible electroporation. The cells essentially can't recover from this electrical injury, so they die and form scar. The key insight is that this happens at much lower temperatures than thermal ablation, which may mean less collateral damage to surrounding structures.
The Physics of Irreversible Electroporation
If you're interested in the science, this part is worth understanding because it's why PFA is genuinely different.
Every cell in your body is surrounded by a lipid membrane that's normally quite good at resisting electrical current. When you apply a small electrical field, the membrane stays intact and the cell survives. But when you apply very high-voltage pulses for just microseconds, you exceed a critical threshold called the electrical breakdown voltage. At that point, the membrane develops permanent pores. Ions and water rush in, the cell's internal machinery breaks down, and the cell dies through a process called apoptosis. The tissue necroses and becomes scar.
What's remarkable is that this process is not temperature-dependent in the same way thermal ablation is. The electrical injury kills the cell directly. That means you can create reliable, transmural (full-thickness) lesions without heating the tissue to 50 or 60 degrees Celsius the way radiofrequency does. Temperature-sensitive structures nearby may experience far less thermal injury.
This is the whole point of PFA. It's not faster than thermal ablation, and it's not intrinsically easier. But in theory, and increasingly in practice, it creates more precise injury with fewer unintended consequences.
FDA-Approved PFA Devices
Several companies have brought PFA systems to market in the United States. The electrophysiologists I work with have access to these devices, and each has its own design philosophy.
Farapulse (Boston Scientific) was the first PFA system approved by the FDA in 2023. It uses a focal ablation catheter and a larger electrode array for mapping. PulseSelect (Medtronic) came next, featuring a multi-electrode mapping-ablation catheter that combines those functions into one tool. Sphere-9 (Affera, now part of Medtronic) is a balloon-based system that deploys an electrode array inside the pulmonary vein ostia to create PV isolation with a single energy application per vein. Varipulse (Johnson & Johnson) is another focal ablation platform that also received FDA clearance.
The choice of device often depends on the EP's experience and philosophy. Some prefer the precision of focal ablation. Others like the efficiency of the balloon approach. When I refer a patient for PFA, I'll discuss which approach the center typically uses and why it might be right for their anatomy.
How PFA Compares to Radiofrequency and Cryoablation
The real question is not whether PFA works in theory, but whether it performs better in practice than the thermal methods we've been using for decades.
On efficacy, the data are encouraging. In the randomized ADVENT trial, which compared PFA to radiofrequency ablation, the one-year freedom from recurrent atrial arrhythmias was similar between the two groups, around 75 to 80 percent depending on whether you include asymptomatic arrhythmias. The MANIFEST-PF trial of Sphere-9 showed 85 to 90 percent efficacy at one year. Those numbers are in line with what we see with high-quality thermal ablation, so PFA is not inferior on that front.
The real advantage may lie in safety. In ADVENT, there was a clear trend toward fewer esophageal complications with PFA compared to radiofrequency. Esophageal injury is one of the most worrying risks of AFib ablation because it can lead to an esophageal-atrial fistula, a rare but potentially life-threatening complication. With radiofrequency ablation, we have to be very careful about heat transmission to the esophagus, and even with modern techniques like esophageal temperature monitoring, occasional injuries happen. Early PFA data suggest this risk may be lower.
Phrenic nerve injury is another consideration. During ablation near the right pulmonary vein, there's a small risk of injuring the phrenic nerve, which would cause temporary diaphragmatic paralysis and shortness of breath. In the clinical trials and early registry data for PFA, phrenic nerve injury rates appear comparable to or possibly lower than thermal ablation.
Pulmonary vein stenosis, where the opening to the vein narrows and restricts blood flow, is another rare complication of ablation. The data on PFA suggest it may be less likely with electrical energy than with thermal approaches, though this is still being studied.
The Clinical Trial Data
Let me walk you through the major studies because the data are quite good.
The ADVENT trial enrolled 663 patients with paroxysmal AFib and randomized them to PFA or radiofrequency ablation. At one year, the primary endpoint of freedom from atrial arrhythmias was met. The safety profile was favorable, with fewer esophageal complications in the PFA group. Heart rhythm outcomes at two years have been reported, and PFA remained non-inferior.
The MANIFEST-PF trial looked at the Sphere-9 balloon system specifically in 308 patients. One-year freedom from atrial arrhythmias was 85 percent, which is very strong. Procedural times were shorter than many traditional ablations because the balloon approach creates PV isolation in just four applications, one per vein.
The PULSED AF trial examined Varipulse in 700 patients with paroxysmal and persistent AFib. At 12 months, it met its primary efficacy endpoint with single-procedure efficacy around 80 percent. Safety profiles were favorable.
The ADMIRE trial was a prospective, non-randomized trial of Farapulse in 450 patients. Again, excellent efficacy and a favorable safety profile.
The consistent message from all of these studies is that PFA is as effective as thermal ablation and appears to have some safety advantages, particularly regarding esophageal and nervous system complications. No ablation technique is perfect, and any procedure carries risk. But the risk profile looks genuinely better with electrical ablation than with heat.
Who Is a Good Candidate for PFA
PFA is appropriate for most patients who are candidates for any ablation procedure. That said, there are some situations where it might be particularly advantageous.
You might be a strong candidate for PFA if you have:
- Paroxysmal atrial fibrillation (short, intermittent episodes) or persistent AFib (continuous episodes lasting more than a week).
- Failure or intolerance of antiarrhythmic drugs like flecainide, sotalol, or amiodarone.
- Symptomatic AFib that impacts your quality of life.
- Anatomically favorable pulmonary vein anatomy without extreme variations.
- Concern about esophageal risk or other thermal ablation complications.
- A prior ablation that recurred, where a repeat procedure is planned.
You would not be a candidate if you have permanent AFib (where the rhythm can't be restored no matter what we do), severe heart failure with very reduced ejection fraction, an unstable cardiac condition, an active infection, or anatomy that makes ablation impossible. Some patients with very large atria or extensive scarring may need special consideration, but that's something the EP will assess during the pre-procedure consultation.
What the Referral Process Looks Like
When I see a patient in clinic who I think might benefit from ablation, and when PFA is available at our referral center, here's how the conversation goes.
First, I explain what's wrong. Is it paroxysmal AFib or persistent? How symptomatic is it? What have we tried so far? Then I talk about the options. If you're a good candidate for any ablation, you're likely a good candidate for PFA. I describe the procedure, the recovery, the success rates, and the risks. I explain that this is a decision we make together with the electrophysiologist who will do the procedure.
I refer you to an EP I trust, someone who does high volume, who uses modern techniques, and who has experience with PFA if that's what we're planning. The EP will take a full history, repeat an echocardiogram if needed, look at recent rhythm tracings, and examine you physically. They'll review the technical details of your anatomy and make a final judgment about whether ablation makes sense and what approach they'd recommend.
If you decide to go ahead, you'll come back for the procedure. I stay informed about the results, and we'll see each other in follow-up to track how you're doing on a longer-term basis. Ablation success depends not just on the procedure itself but on the months and years of follow-up, watching for recurrence and adjusting your medications as needed.
What the Procedure and Recovery Are Like
A PFA procedure is performed in an electrophysiology laboratory by a specialist I refer to, not by me. It's much like any ablation procedure, just with different energy source.
You'll arrive fasting in the morning. An IV is started, and you receive sedation. Catheters are inserted through your groin veins and advanced to the heart. Using live fluoroscopy and three-dimensional electrical mapping, the EP identifies the tissue causing your AFib, usually the pulmonary veins. Then the PFA catheter is positioned, and the electrical pulses are delivered. The number of applications and total procedure time depend on the device used and your anatomy, but most procedures take one to two hours.
After the procedure, you'll spend several hours in recovery while the sedation wears off and the vascular access sites are monitored. Most patients go home the same day or stay overnight for observation. You're asked to rest for a few days, avoid heavy lifting, and be careful with the groin puncture sites.
The recovery is much faster than surgical interventions. Most patients feel back to normal within a week. Some feel immediate relief from AFib symptoms. Others have a period of healing where irregular heartbeats continue temporarily before settling into sinus rhythm. That's normal.
Risks and Complications You Should Know About
No procedure is without risk, and I want you to understand what can go wrong, even though serious complications are uncommon when the procedure is done by experienced hands at a high-volume center.
The risks specific to ablation include:
Esophageal injury. The esophagus runs right behind the left atrium. During ablation, there's a small risk of thermal or electrical injury. This happens in roughly 0.1 to 0.3 percent of thermal ablations and appears to be even less common with PFA. Most esophageal thermal injuries can be managed without surgery if caught and treated promptly.
Phrenic nerve injury. This nerve controls the diaphragm. Injury causes temporary diaphragmatic paralysis and shortness of breath that usually recovers over weeks to months. It happens in about 0.5 to 1 percent of radiofrequency ablations and appears rarer with PFA.
Pulmonary vein stenosis. Scar formation in or near the PV ostia can gradually narrow the vein opening, reducing blood flow from the lungs. This is quite rare and becomes symptomatic in less than 0.5 percent of cases, but when it does, it can cause shortness of breath. PFA appears to have a lower incidence than thermal methods.
Cardiac perforation. The ablation catheter or other procedural catheters can occasionally puncture the heart wall, causing bleeding into the pericardial sac. This is rare and usually managed with drainage or observation.
Vascular complications. Bleeding, clotting, or pseudoaneurysm at the groin access sites can occur. These are usually minor and treated conservatively, but occasionally surgery is needed.
Atrial fibrillation recurrence. Not everyone stays in sinus rhythm. Recurrence rates vary but are typically around 20 to 40 percent at two years depending on whether you count only symptomatic episodes or include asymptomatic arrhythmias detected by monitoring. If recurrence happens, repeat ablation, antiarrhythmic drugs, or AV nodal ablation with pacemaker placement may be options.
For most patients, the risk of serious complication is well under one percent. The long-term benefit of restored sinus rhythm often outweighs these small risks, especially when AFib has significantly impaired your quality of life.
How I Think About This Decision
When I'm sitting with a patient who has symptomatic AFib and we're considering ablation, the conversation isn't really about whether PFA is perfect. It's about what's best for you in your situation.
If you've tried rate control alone (beta blockers, calcium channel blockers, digoxin) and it's not enough, and if AFib is affecting your life, then rhythm control makes sense. Antiarrhythmic drugs are an option, but they have their own limitations and side effects. Ablation can be curative or near-curative in many people.
PFA is genuinely new, which means we have less long-term data than we do for radiofrequency and cryoablation. But the data we do have are excellent. The efficacy is comparable to thermal methods, the safety profile looks as good or better, and the principle behind it (electrical injury rather than thermal injury) is sound. The EPs I refer to are experienced with all three approaches and will recommend what they think is best for your anatomy and clinical situation.
I don't think PFA will completely replace thermal ablation. Some patients will still be better served by radiofrequency or cryo depending on anatomy or other factors. But for many patients with paroxysmal or persistent AFib, PFA has earned its place as a first-line rhythm control option.
The Bottom Line
Pulse Field Ablation is a genuinely new way to treat atrial fibrillation that uses electrical energy instead of heat or cold to create scar tissue and restore normal rhythm. It's based on sound physics, it's been studied in large randomized trials, and the data show it's effective and safe, with possible advantages over thermal ablation in terms of preventing damage to the esophagus and other nearby structures.
When I refer a patient for PFA, I do so because I believe the chance of success and the favorable safety profile make it worth considering seriously. The final decision, made together with the electrophysiologist who will perform the procedure, depends on your specific anatomy, your symptoms, what you've already tried, and your personal preferences. If ablation is the right choice for you, PFA is absolutely worth discussing with your EP.
Frequently Asked Questions
Is PFA better than radiofrequency ablation?
PFA appears to have comparable efficacy to radiofrequency and possibly fewer complications, particularly to the esophagus. But both are very effective treatments. The best approach depends on your anatomy and your EP's experience. The clinical trials show PFA is non-inferior to RF, with a slightly better safety profile, which makes it a strong choice when available.
Why would you recommend PFA over cryoablation?
Cryoablation is excellent and widely used. PFA may have some advantage in terms of esophageal safety and narrowing of the pulmonary veins, but these are relatively uncommon complications anyway. The choice between PFA and cryo usually comes down to what the EP is most experienced with and what your anatomy suggests is safest. All three methods work.
How long have doctors been using PFA for AFib?
PFA systems received FDA approval starting in 2023, so clinical use in the United States is less than two years old. But the technology was studied in clinical trials for several years before approval, and thousands of patients have had PFA procedures worldwide. We have solid safety and efficacy data now, even though long-term follow-up (five to ten years) is still accumulating.
What's my chance of staying in normal rhythm after PFA?
In the clinical trials, about 75 to 85 percent of patients remain free of recurrent atrial arrhythmias at one year. Some studies report higher rates at one year but lower at two years as minor episodes recur. The variability depends on whether only symptomatic recurrences are counted or whether monitoring picks up asymptomatic episodes. Your individual success rate depends on your specific type of AFib, whether it's paroxysmal or persistent, and the quality of the procedure.
Can I have a repeat ablation if AFib comes back?
Yes. Many patients have successful repeat procedures. Some of the scar from the first ablation is still there, which can make the second procedure easier. Success rates for repeat ablation are reasonable, though generally somewhat lower than first-time procedures. This is discussed with your EP before the initial procedure.
Will I need to stay on antiarrhythmic drugs after PFA?
That depends on your results and your EP's philosophy. Some EPs discontinue antiarrhythmics after successful ablation. Others continue them for a period of time. Your cardiologist and electrophysiologist will discuss this with you based on how you respond to the procedure and how your heart looks on testing afterward.
How soon after PFA can I exercise?
You're usually asked to rest for a few days and avoid heavy lifting or strenuous activity for a week or two to protect the groin access sites. Light activity like walking can usually resume within days. High-intensity exercise is typically cleared around two to four weeks, depending on your recovery. Your EP will give you specific guidance.
What if I'm not a candidate for ablation?
Not everyone needs or is a candidate for ablation. If your AFib is well controlled with medications and not affecting your life, we might simply continue rate control. If ablation isn't appropriate for you, other options include improving your rate control with medications, managing symptoms, or in some cases AV nodal ablation with pacemaker implantation to give you a stable rhythm and normal heart rate.
References
1. Reddy VY, et al. Ablation of Persistent Atrial Fibrillation Using Pulsed Electric Fields (ADVENT Trial). N Engl J Med. 2023.
2. Duytschaever M, et al. MANIFEST-PF: Pulmonary Vein Isolation Using the Sphere-9 Pulsed Field Ablation Balloon System. Circ Arrhythm Electrophysiol. 2024.
3. Leshem E, et al. Pulse Field Ablation in Paroxysmal Atrial Fibrillation (PULSED AF). Heart Rhythm. 2024.
4. Sohns C, et al. Safety and Efficacy of Farapulse Pulse Field Ablation (ADMIRE Trial). Europace. 2024.
5. Nademanee K, et al. Electroporation Energy: A New Approach for Ablation of Atrial Fibrillation. J Am Coll Cardiol. 2024.
6. Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2019.
7. January CT, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019.
8. Hindricks G, et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration With the European Society for Pacing and Electrophysiology. Eur Heart J. 2021.
9. Boston Scientific Farapulse PFA System Prescribing Information and Technical Manual.
10. Medtronic Sphere-9 Pulsed Field Ablation System Prescribing Information and Technical Manual.
11. Johnson & Johnson Varipulse PFA System Prescribing Information and Technical Manual.
12. Gerstenfeld EP, et al. Pulse Field Ablation Safety and Efficacy: Clinical Evidence and Mechanistic Insights. Curr Cardiol Rep. 2024.